**Protocol for Medicine Optimisation Reviews for Direct-Acting Oral Anticoagulants (DOACs) in Atrial Fibrillation (AF)**

**Applies to:**

Pharmacists and GPs working in an NHS Healthcare Trust or Place.

This protocol is produced by Cheshire and Merseyside Healthcare Partnerships (HCP).

**Aims:**

* To review all patients currently prescribed a DOAC for AF, assess whether treatment is still clinically appropriate and check the dose is correct.
* To review patients currently prescribed apixaban to determine if an alternative DOAC with a lower acquisition cost is clinically appropriate and change if safe to do so after discussion with the patient/carer.

**Background:**

Direct-acting oral anticoagulants (DOACs) or non-vitamin K antagonist oral anticoagulants (NOACs) are an alternative anticoagulant to prevent strokes in patients with Atrial Fibrillation (AF). All patients with the following should be considered for an oral anticoagulant ([NICE NG1961](https://www.nice.org.uk/guidance/ng196)):

* symptomatic or asymptomatic paroxysmal, persistent or permanent atrial fibrillation
* atrial flutter
* a continuing risk of arrhythmia recurrence after cardioversion back to sinus rhythm

The Cheshire and Merseyside Integrated Care Board (ICB) are supporting the review of all patients currently receiving a Direct Oral Anticoagulant (DOAC) or non-vitamin K antagonist oral anticoagulant (NOAC) for stroke prevention in AF. This project is supported by the Northwest Cardiac Strategic Clinical Network and Cardiovascular Board.

All patients on a DOAC for AF should have a medicine optimisation review to ensure their existing DOAC is appropriate according to recent bloods and weight. All patients prescribed any oral anticoagulant (OAC) should discuss the options with a healthcare professional at least once a year [NICE QS93](https://www.nice.org.uk/guidance/qs93)2. Adherence and compliance should be assessed regularly to support patients to take medication appropriately and safely. Stroke and bleeding risk will change over time and must be recalculated at least annually. Blood monitoring including Haemoglobin (Hb), liver and renal function should be monitored at least annually, and more regularly in people with renal dysfunction, over the age of 75 years or those who are frail. The 2018 European Heart Rhythm Association Guidelines ([EHRA 2018](https://academic.oup.com/eurheartj/article/39/16/1330/4942493)3) recommends monitoring as per table 1 (see Appendix 1).

Currently, all DOACs (edoxaban, dabigatran, rivaroxaban and apixaban) are recommended as options for anticoagulation in the NICE AF Guidelines [(NG1961)](https://www.nice.org.uk/guidance/ng196) considering individual patient bleeding risks and co-morbidities. NHS England (NHSE) recently published [Commissioning Guidance](https://u4978464.ct.sendgrid.net/ls/click?upn=f3Ut4HzWYQjyfZa8pd8QHN-2FdG7ICCLVOVowUM3amfGLBD4ma7cullDKd-2F1iBLaRZTb8JkRsWIst1JEcnV-2FLqOxlK-2F8Yyn-2B2KguyNedbM3m2cZ2V-2BPM77Kpni-2F2ovfgKlIsWg-2F6hZBz2-2BRichhv17KwnjXZVOnNHx9tAhwSUShizeYM2cd2ffIci4T2MjGQVqkPP__C0iibycwa8saRXBwPDH5uJC6YA8ET1RZ-2FrNPY-2FBMR7mYOwRY5TD6i7RDlyxlzqgQwDaw8xh2-2FKYD4Ue-2FFJ1LfqrA0kxCS4zykGD58XisbikWU-2F8G7-2FCtFSleZDW9zyk1Z4oolLqRGsyeyZmYchZNZvG9iqel1J0Qb2jgNb-2F9IvtcVjNOf-2BYR34tmowCb-2BFRJZN9a6iLe390lotULHCVDog-3D-3D) 4 for DOACs which recommends that clinicians should use edoxaban, where clinically appropriate, consistent with the latest guidance from NICE 1. This approach has also been endorsed by the UK’s leading stroke charity, Stroke Association.

There are no head-to-head comparative trials that demonstrates that one DOAC is significantly better than another and treatment should be based on individual patient factors and bleeding risk. Patients newly diagnosed with AF who require anticoagulation should be initiated on edoxaban unless there is a clinical reason to use warfarin or another DOAC.

Objectives:

* To optimise the care of patients on a DOAC
* To identify patients in whom a DOAC is not appropriate
* To identify patients in whom the dosage of DOAC prescribed needs amending: either increasing or decreasing
* To identify patients who need (additional) monitoring
* To identify patients on interacting medication and change as appropriate
* To identify patients on concomitant antiplatelet and/or anticoagulants and adjust treatment accordingly
* To identify patients prescribed a DOAC with the current highest acquisition cost (apixaban) to review if they are clinically appropriate to change to another DOAC of a lower acquisition cost
* To provide outcomes of the reviews to the HCP for analysis. No patient identifiable data will be shared.

**Rationale:**

To ensure that all patients are on an appropriate DOAC and dose regime for their individual renal function, liver function, weight, co-morbidities and medication, to ensure optimal oral anticoagulant (OAC) therapy. Given the current significant price difference between apixaban and the other DOACs available, patients should also be reviewed to consider if an alternative DOAC of a lower acquisition cost, could be prescribed instead of apixaban.

**Inclusions:**

* All patients with AF prescribed a DOAC will be reviewed to ensure medicine optimisation of their DOAC and amended accordingly, if appropriate

All patients with AF prescribed apixaban should be reviewed to consider changing them to a DOAC of lower acquisition cost as part of the medicine's optimisation review.

**Exclusions:**

* Patients on a DOAC for another documented indication other than AF

**Responsibilities:**

To be agreed at Place level;

* Each practice should determine whether a pharmacist or GP will undertake the optimisation reviews of DOACs. The method has been written as per a pharmacist review.
* Pharmacy technicians could be responsible for running the EMIS search and report, as per protocol and highlighting patients with any outstanding monitoring to the pharmacist or GP.
* The pharmacist or GP is responsible for undertaking the reviews, as per protocol and training provided.
* The pharmacist or GP undertaking the review is responsible for ensuring the patient has given verbal consent, which is documented in the PMR, if further advice needs to be sought from a specialist external to the GP practice.
* GP Practice to agree for non-identifiable patient information to be collated for service evaluation at a regional level.
* The GP is responsible for agreeing for the work to be carried out in the practice, ensuring all monitoring and values are up to date and for following up any patients identified during the project that require further review.

**Other Useful Resources and Links:**

Electronic Medicines Compendium for DOAC SPCs [EMC](https://www.medicines.org.uk/emc)5

Refer to local Formulary and guidance

Appendix 1 - Table 1: Monitoring required for DOACs

Appendix 2 - Table 2: [CHA2DS2-VASc](https://www.mdcalc.com/cha2ds2-vasc-score-atrial-fibrillation-stroke-risk)6 risk factor ([EHRA 2020](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehaa612/5899003)7).

- Table 3: [HAS-BLED](https://www.mdcalc.com/has-bled-score-major-bleeding-risk)8 – Assessment of bleeding risk in patients with atrial

fibrillation ([EHRA 2020](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehaa612/5899003)6)

* Table 4: [ORBIT 9](https://www.mdcalc.com/orbit-bleeding-risk-score-atrial-fibrillation) – Simple bedside score to assess bleeding risk in AF ([NICE NG1961](https://www.nice.org.uk/guidance/cg180))
* Table 5: Risk Categories and Bleeding Events of ORBIT and HAS-BLED

Appendix 3 – Table 6 – Prescribing parameters for all DOACS

Appendix 4 – Table 7 of interactions with DOACs

Appendix 5 – Checklist for patient/carer consultation

Appendix 6 – Decision Aid for Medicines Optimisation Review of Patients Prescribed

Apixaban

Appendix 7 – EMIS search/report and how to apply

Appendix 8 – EMIS template and how to import to EMIS

Appendix 9 – Final Outcomes Report

**Method:**

|  |  |
| --- | --- |
| **Action** | **Who is responsible** |
| **DOAC Review** | |
| 1. Gain agreement from the GP practice to run the EMIS search and report and to review all patients with NV-AF prescribed DOACs, as per protocol. Gain agreement from the GP practice to review patients prescribed apixaban, to determine if an alternative DOAC with a lower acquisition cost is clinically appropriate, then change. Agree with GP practice action to be taken if outstanding monitoring is identified. | **Pharmacist / GP** |
| 1. Notify the Local Pharmaceutical Committee (LPC) and GP practice staff of work being undertaken. | **Pharmacist/Technician** |
| 1. Run the approved EMIS search and reports to identify all patients in the practice on existing DOAC therapy – edoxaban, apixaban, rivaroxaban or dabigatran who also have a code for AF or atrial flutter. | **Technician** |
| 1. Check EMIS report to see if monitoring of U+E’s, FBC, LFTs, BP\*, HR\* and actual body weight are within the preceding 3 months and if not, highlight any required monitoring to the GP practice or action as agreed by the GP practice.   Review each patient once all values\*\* have been received and documented in the patient’s medical record (PMR).  Each practice should consider how best to recall patients for monitoring. Factors to consider include:   * Number of patients * How and when the medicines management team will check that monitoring is complete * How to update the patient list as patients join and leave the practice   **\*NB: consider if HR >100 bpm, refer to GP for rate control. BP consistently above 140/90 should be discussed with GP or reviewed according to local guidelines.**  **\*\*NB: as per local reference ranges** | **Pharmacist/Technician** |
| 1. The EMIS report highlights patients with the following:    * Possible valvular heart disease    * Possible unlicensed indications for DOAC treatment    * History of thromboembolism    * Two oral anticoagulants on current medication   **NB. If you identify that a patient is currently taking a DOAC for an indication other than AF it is good practice to confirm the dose and duration of treatment is appropriate.** | **Technician** |
| **In consultation, run the EMIS DOAC Review Template (see Appendix 8 for how to install)** | |
| 1. Calculate and update the CHA2DS2-VASc8 score using the EMIS calculator     **NB: Patients with a CHA2DS2-VASc =1 in men or =2 in women should**  **be considered for an oral anticoagulant (OAC).**  **Patients with a CHA2DS2-VASc score >2 in men and >3 in women:**  **It is recommended that these patients should be prescribed an OAC.** | **Pharmacist** |
| 1. Calculate and update the HAS-BLED score using table 3 in Appendix 2, to assess the risk of bleeding in people on anticoagulation. NICE [NG196](https://www.nice.org.uk/guidance/ng196)1 AF Guidelines recommends using the ORBIT score to calculate the risk of bleeding. Until this is embedded into EMIS it is acceptable to continue using the HAS-BLED score or calculate both scores to make an informed decision (see below).   Refer to GP if clarification needed for modification, monitoring or advice, if there is no documentation that the following risk factors have been considered:   * Uncontrolled hypertension * Concurrent medication that will increase bleeding risk; * Anti-platelet medication e.g. aspirin * Non-steroidal anti-inflammatory drugs (NSAIDs) * SSRI’s or SNRI’s * Harmful alcohol consumption above national recommendations (if noted on PMR)   Calculate the ORBIT score9 using Appendix 2, table 4  Offer monitoring and support to modify risk factors for bleeding, including:   * uncontrolled hypertension (see NICE's guideline [NG136](https://www.nice.org.uk/guidance/ng136)10 on hypertension in adults) * concurrent medication, including antiplatelets, selective serotonin reuptake inhibitors (SSRIs) and non-steroidal anti-inflammatory drugs (NSAIDs) * harmful alcohol consumption (see NICE's guideline [CG115](https://www.nice.org.uk/guidance/cg115)11 on alcohol-use disorders: diagnosis, assessment and management of harmful drinking and alcohol dependence) * reversible causes of anaemia.   With patient permission, Secondary Care advice with a Specialist Pharmacist may be sought via email if there are additional queries or concerns that the pharmacist or GP is unable to resolve. If no local specialists are available advice may be requested from [joanne.bateman@nhs.net](mailto:joanne.bateman@nhs.net), Project Lead and Chair of Pharmacist Cardiac and Stroke Forum, Northwest Strategic Clinical Network. Queries will be escalated for consultant advice if required.  Particularly complicated patients can be referred to the AF Specialist Clinic at Liverpool Heart and Chest Hospital (LHCH) or the Clinical Haematology Service, Roald Dahl Haemostasis and Thrombosis Centre, Liverpool University Hospitals NHSFT for advice about anticoagulation.  **Consider:**  A high bleeding risk score should generally not result in withholding OAC. Rather, bleeding risk factors should be identified, and treatable factors corrected. If patients are on concomitant anti-platelets, review if these are appropriate. Consider stopping if >1 year post-acute coronary syndrome (ACS) or stable coronary artery disease. Discuss with GP/Specialist if necessary.  Consider gastro-protection with appropriate concomitant anti-platelets. | **Pharmacist** |
| 1. Calculate the Creatinine Clearance (CrCl)  * All DOACs may require a dose adjustment based on renal impairment * **Creatinine clearance must be used for calculating renal function** using the Cockcroft and Gault equation (see below). eGFR is **not** a suitable alternative:   CrCl (ml/min )= (140 – age) x wt (kg) x 1.04 (female) or 1.23 (male)  serum creatinine (micromol/l)   * The actual body weight must be used to calculate CrCl   **NB The EMIS clinical system used in primary care has an inbuilt Cockcroft-Gault based renal function calculator which can be used to dose DOACs. EMIS recognises if the patient is prescribed a DOAC and will use actual body weight to calculate CrCl for these patients. The exception are patients taking Dabigatran who are also obese, in this case the calculator uses ideal body weight. In these cases, you should record the creatinine clearance for actual body weight in the consultation. Actual body weight was used in AF trials for all DOACs.**   * Another option is to use the MD+ CALC Creatinine Clearance calculator (it can be downloaded as an app to an apple or android device). Always use the most up to date values and check the default units are correct when entering weight and serum creatinine. It would be good practice for the clinician reviewing the patient to document what method was used * Document the method used to calculate CrCl on the template   **NB:**   * **Pts with CrCl < 15mls/min – refer to GP/Specialist for review as contraindicated (if CrCl borderline 15 – 20mls/min this should be discussed with GP to ensure a DOAC is still appropriate)** * **Pts on Dabigatran and CrCl<30mls/min – contraindicated and refer to GP/Specialist for alternative DOAC** | **Pharmacist** |
| 1. Confirm if the current DOAC dose and indication is correct and the current DOAC dose is appropriate for patients with AF, according to current parameters – see table 6 in Appendix 3 and SPC of each DOAC. | **Pharmacist** |
| 1. Check all medication for any significant drug interactions including hospital prescribed medication, OTC and herbal/alternative therapy– see table 7 in Appendix 4 and SPCs for full details.   **NB: If prescribed anti-platelets, consider whether these need to be**  **continued and if unsure, discuss with Specialist, as per point 7.** | **Pharmacist** |
| 1. Discuss any patients on incorrect dose/significant interactions/safety concerns with GP.   NB:  Where the efficacy of either the DOAC or another medication is affected please ensure this is discussed with the GP and/or relevant specialist e.g. antiepileptics | **Pharmacist** |
| 1. Following agreement by the GP practice, patients on apixaban should be reviewed as per the Decision Aid for Medicines Optimisation Review of Patients Prescribed Apixaban (appendix 6), to consider if an alternative DOAC is clinically appropriate | **Pharmacist** |
| 1. Discuss any other identified issues or queries with the GP as appropriate and document the outcome. | **Pharmacist** |
| 1. Contact the patient to review adherence, side effects, adverse drug reactions (ADRs) or any issues raised during the review. Discuss and agree with patient any recommended changes | **Pharmacist** |
| **Patient review and informed discussion via phone or virtual consultation** | |
| 1. Contact the patient/carer as agreed by the practice (telephone or virtual) and go through the patient section of the EMIS DOAC template, checking for any;  * GI symptoms (consider addition of PPI or discuss with GP) * Swallowing difficulties * Bleeding * OTC or herbal medications * Adherence * Adverse drug reactions * Side-effects * Excessive alcohol intake * Re-calculate HASBLED/ORBIT score if necessary * Check if patient uses a monitored dosage system and inform community pharmacy of any changes.   Use the checklist to ensure you cover all the relevant counselling | **Pharmacist** |
| 1. Advise patients of the issues identified e.g. DOAC agent to be changed or dose change and make the appropriate changes or if there are any interactions that patients need to be aware of | **Pharmacist** |
| 1. For any concerns or further issues identified – discuss with the GP or Specialist and document the outcome. Advise patient that you will inform them of outcome of discussion with GP or Specialist. | **Pharmacist** |
| 1. Use a suitable code such as ’*Medication Review done by Medicines Management Pharmacist’*\* and set an appropriate follow up review date that considers the criteria in Appendix 1. Table 1.   **\*NB: local agreement may differ where and how to record on PMR** | **Pharmacist** |
| 1. Document the outcomes of the DOAC review on the final outcomes report (see Appendix 9), as agreed at Place level\*   **\*No patient identifiable data should be collected on the outcome report** | **Pharmacist** |

**Agreement to Protocol**

|  |  |
| --- | --- |
| Signature of practice prescribing lead/ manager |  |
| Practice name |  |
| Date |  |

**Appendix 1**

**Table 1: Blood monitoring required for DOACs (**[**EHRA 2018**](https://academic.oup.com/eurheartj/article/39/16/1330/4942493)**3)**

|  |  |
| --- | --- |
| **Monitoring** | |
| **Interval** | **Patient Cohort** |
| Yearly | Patients other than those specified below |
| 6 – monthly | ≥75 years (especially if on dabigatran) or frail |
| X - monthly | If renal function CrCl ≤60 mL/min: recheck interval = CrCl/10 (= X value) |
| If needed | Any intercurrent condition that may impact renal or hepatic function as identified by the GP/NMP |

**Appendix 2**

|  |  |
| --- | --- |
| **Table 2: CHA2DS2-VASc risk factor (ESC 2016)** | |
| **Congestive heart failure**  Signs/symptoms of HF or objective evidence of reduced left ventricular EF | +1 |
| **Hypertension**  Resting BP>140/90 mmHg on at least two occasions or current antihypertensive treatment | +1 |
| **Age ≥75 years** | +2 |
| **Diabetes mellitus**  Fasting glucose >125mg/dL (7mmol/L) or treatment with oral hypoglycaemic agent and/or insulin | +1 |
| **Previous stroke, transient ischaemic attack, or thromboembolism (arterial)** | +2 |
| **Vascular disease**  Previous myocardial infarction, peripheral artery disease, or aortic plaque | +1 |
| **Age 65-74 years** | +1 |
| **Sex (female=1)** | +1 |
| **Score** |  |

|  |  |
| --- | --- |
| **Table 3: HAS-BLED** – Assessment of bleeding risk in patients with AF (ESC 2016) | |
| Hypertension (Systolic >160mmHg) | 1 |
| Abnormal renal function - Dialysis, transplant, serum Cr >200 micromol/L | 1 |
| Abnormal liver function – cirrhosis, bilirubin> x 2 upper limit, AST/ALT/ALP X 3 upper limit | 1 |
| Stroke – previous ischaemic or haemorrhagic stroke | 1 |
| Bleeding tendency or predisposition – previous major haemorrhage or anaemia or severe thrombocytopenia | 1 |
| Labile INRs (if on warfarin/VKA) – TTR <60% | 1 |
| Elderly (e.g. age > 65 years or extreme frailty) | 1 |
| Drugs (e.g., concomitant aspirin, NSAID) | 1 |
| Alcohol intake at same time (>14 units per week) | 1 |
| Maximum score | 9 |
| A HAS-BLED score >3 suggests that caution is warranted when prescribing oral anticoagulation that regular review is recommended and that the reversible bleeding risk factors are addressed. | |

|  |  |
| --- | --- |
| **Table 4 – ORBIT** | |
| **Selection Criteria** | **Points** |
| Older age >75 years old | 1 |
| Reduced Haemoglobin /reduced Haematocrit/Anaemia  Hb <130g/L Male; Hb <120g/L  Hct: <40% Males, <30% Females  History of anaemia | 2 |
| Bleeding history | 2 |
| Insufficient renal function eGFR<60mg/dL | 1 |
| Treatment with antiplatelet agents | 1 |
| **Score (maximum score = 7 points)** |  |

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| **Table 5 – Risk categories and bleeding events in Validation Cohorts** | | | | | | |
|  | **Risk Categories** | | | **Bleeding Events in Validation Cohorts**  **(Per 100 patient-years)** | | |
|  | **Low** | **Intermediate** | **High** | **Low** | **Intermediate** | **High** |
| **HAS-BLED** | **0-1** | **2** | **>3** | **1.02-1.13** | **1.88** | **>3.74** |
| **ORBIT** | **0-2** | **3** | **>4** | **2.4** | **4.7** | **8.1** |

**Appendix 3**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Table 6: Dosing for DOACs – see SPC for full details at emc.medicines.org.uk** | | | | |
|  | **Edoxaban** | **Apixaban** | **Rivaroxaban** | **Dabigatran** |
| **Standard dose** | **60mg daily** | **5mg twice daily** | **20mg daily** | **150mg twice daily** |
| **Reduce dose in the following patients** | **30mg daily**   * CrCl ≤50ml/min * Weight ≤60kg * On interacting medication   (Ciclosporin, dronedarone, erythromycin, ketoconazole) | **2.5mg twice daily**  If CrCl 15-29ml/min  **OR** 2 of the following criteria:   * ≥80yrs * Creatinine ≥133 * Weight <60kg | **15mg daily**  If CrCl <50ml/min | **110mg twice daily**   * > 80 years * On concomitant verapamil   Consider reduced dose based on individual assessment of the thromboembolic risk and risk of bleeding if:   * 75-80yrs and high bleeding risk * Calc CrCl 30-50mls/min * Gastritis, oesophagitis or GI reflux * At increased risk of bleeding   Close clinical surveillance is needed if patient weighs <50kg |

**Appendix 4**

|  |  |  |  |
| --- | --- | --- | --- |
| **Table 7: Interactions with DOACs – see SPC for full details at emc.medicines.org.uk** | | | |
| **Dabigatran** | **Rivaroxaban** | **Apixaban** | **Edoxaban** |
| Ketoconazole, ciclosporin, itraconazole, tacrolimus, dronedarone, ritinovir and combinations -**CONTRAINDICATED** | Azole antimycotics (e.g.ketoconazole, voriconazole, itraconazole) **– NOT RECOMMENDED** | Azole antimycotics (e.g.ketoconazole, voriconazole, itraconazole) **–NOT RECOMMENDED** | Erythromycin, oral ketoconazole, ciclosporin and dronedarone – **reduce to 30mg** |
| Amiodarone and quinidine increase dabigatran levels – clinical surveillance. Patient with mild-mod renal impairment are at higher risk of bleeding | Rifampicin, phenytoin, carbamazepine, phenobarbital or St.Johns Wort – significant reduction in efficacy of rivaroxaban – **best AVOIDED.** | Rifampicin, phenytoin, carbamazepine, phenobarbital or St.Johns Wort – 50% reduction in serum apixaban level- **CAUTION, seek specialist advice and discuss risk** | Quinidine, verapamil + amiodarone can increase edoxaban – **no dose change** |
| Verapamil – increases dabigatran levels. **Reduce dose to 110mg BD** and monitor. Take dabigatran and verapamil at the same time. | HIV protease inhibitors e.g. ritonavir – **NOT RECOMMENDED** | Aspirin, clopidogrel, antiplatelets and NSAIDS – increased bleeding risk | Aspirin and antiplatelets – increased bleeding risk  Chronic NSAID use –**NOT RECOMMENDED** |
| Ticagrelor, clopidogrel, prasugrel, aspirin etc. consider dose reduction | NSAIDS/antiplatelets: Ticagrelor, clopidogrel, prasugrel, aspirin etc. increased bleeding risk. | HIV protease inhibitors e.g. ritonavir – **NOT RECOMMENDED** | Rifampicin, phenytoin, carbamazepine, phenobarbital or St. John’s Wort – reduces edoxaban levels, reducing effect - **CAUTION, seek specialist advice and discuss risk** |
| Rifampicin, carbamazepine, phenytoin, St. John’s Wort – **NOT RECOMMENDED** | Dronedarone – inadequate data. **AVOID** | Diltiazem, amiodarone, verapamil and quinidine increase apixaban level **- no dose adjustment necessary.** | HIV protease inhibitors – studies not done |
| Posaconazole – no experience - CAUTION | MHRA warning for potential interaction with erythromycin resulting in increased risk of bleeding when combined |  |  |

**Appendix 5 -** Medicine Optimisation Reviews for DOACs in AF – Patient/Carer Contacted - Consultation Checklist

DOACs - Apixaban (Eliquis®), Dabigatran (Pradaxa®), Edoxaban (Lixiana®), Rivaroxaban (Xarelto®)

|  |
| --- |
| Counselling point **before** starting review |
| Explain that all patients with non- valvular Atrial Fibrillation who are prescribed a DOAC for stroke prevention are being reviewed to ensure it is appropriate and the correct dose. No need for alarm or concern. |

Follow the **EMIS Template** and cover these key questions and counselling points with the patient and/or carer **BEFORE** considering changes to DOAC treatment

|  |  |
| --- | --- |
| Question\Counselling Point |  |
| **Check adherence with DOAC treatment**. | This includes taking Rivaroxaban 15mg or 20mg with food. Ensure the patient is aware of the importance of adherence with these medications. |
| **Check if the patient has experienced any ADRs or side effects.** | Report via yellow card scheme where necessary and update the clinical record. Seek advice from GP or specialist if needed. |
| **“Do you suffer with any symptoms such as: acid reflux, heartburn, stomach pains etc.?”** | Is the patient taking gastro protection medication regularly? Refer to the GP for gastro protection if not already prescribed or if already prescribed gastro protection and still symptomatic |
| **“Any current symptoms of bleeding?”** | Ensure patient knows the signs to be aware of and to contact their GP or, if severe, to go straight to hospital or call an ambulance.  Bruising or bleeding under the skin • Blood in the urine • Coughing up blood • Vomiting blood or material that looks like ground coffee • Nose bleeds or cuts that take a long time to stop bleeding • Tar-coloured stools • Dizziness or sudden headache • Unexplained tiredness • Abnormal vaginal bleeding, including heavier or prolonged menses •new confusion |
| **“Any swallowing problems with tablets?”** | Apixaban, rivaroxaban and edoxaban tablets can be crushed and mixed with water, apple juice or apple puree.  Patients with long term swallowing problems should remain on apixaban, edoxaban or rivaroxaban.  Dabigatran **must not** be crushed so is not suitable for patients with swallowing problems. |
| **“Are you taking any other medication (e.g. from the hospital), OTC or herbal medicines?”** | For example, Aspirin, NSAIDS, St. John’s Wort etc. ensure the patient is aware to always check with a pharmacist before using any OTC or herbal meds due to risk of interactions with anticoagulants. |
| **Check on alcohol consumption - Re-calculate HASBLED score as needed**. | If appropriate, remind patient of current government guidelines; no more than 14 units of alcohol per week for men and women spread over at least 3 days with several alcohol-free days per week. |
| **“Have you ever had a blood clot? Or been told you have a blood clotting problem?”** | This is to check any history of DVT or PE (including any unusual clots such as LV thrombus or portal vein thrombosis) or any thrombophilia that may not have been recorded on the PMR. This would highlight if the patient is on a DOAC for an off license use (LV thrombus) or requires a different dose e.g. DVT/PE  Note: only arterial clots are considered as a thromboembolism when calculating CHA2DS2-VASc (excludes DVT/PE) but this may highlight different dose requirement |
| **“Have you ever had an operation on your heart?”** | This is to check if the patient may have had a mechanical heart valve replacement or valve repair that has not been recorded on the PMR which may contraindicate treatment of any DOAC. |
| **IF APPROPRIATE:** **Check if the patient is pregnant or breastfeeding** | DOACs are normally contraindicated during pregnancy and women of child-bearing potential should avoid becoming pregnant during treatment. Advise to use reliable contraception and discuss with the GP if planning pregnancy. DOACs also normally contraindicated during breastfeeding, it should be decided whether to cease therapy or to discontinue breastfeeding. Seek specialist advice from haematology if pregnant or breastfeeding. |
| **Explain decision to change patient to another DOAC or change the dose of existing therapy if relevant** | Advise patient of necessary changes and why.  If DOAC agent changing to alternative e.g., apixaban to edoxaban, explain rationale – works as well, clinically appropriate for the patient and will facilitate cost savings to the NHS |
| **If further advice is needed from a specialist outside of the GP practice gain patient consent to discuss** | Patients already discussed with the GP but who need further information, advice may be sought from a secondary care specialist pharmacist who may discuss with a Cardiologist if necessary. This will require documented patient consent.  Complicated patients can be referred to the Specialist AF Clinic at LHCH. |

|  |  |
| --- | --- |
| Counselling points | After decision of DOAC change |
| **If DOAC treatment to be changed** | If apixaban is going to be changed to another DOAC, assure the patient that the new DOAC will have the same beneficial effect as their current anticoagulant and their risk of stroke due to AF will be controlled in the same way as before.  Explain that their full history and medication has been reviewed and the new DOAC is appropriate and the most cost-effective. This change is in accordance with regional guidance as agreed by local experts in AF and anticoagulation. |
| **Changing from one DOAC to another** | When changing from one DOAC to another advise the patient to use up the remainder of their existing DOAC first. It is important that the new DOAC is started when the NEXT dose was due of the ORIGINAL DOAC. The dose should then be continued as labelled (see below for how change in DOAC directions should be explained to each patient)  **Twice daily DOAC changing to a once daily DOAC:**  Finish the last dose of the existing twice daily DOAC and start the new DOAC 12 hours later (when the existing DOAC would have been due). Then continue on the new DOAC every 24 hours, once a day.  **Once daily DOAC to twice daily DOAC:**  Finish the last dose of the existing once daily DOAC and start the new DOAC 24 hours later then continue taking the new DOAC every 12 hours twice a day |
| **Dosage and Directions** | Clearly explain the dosage and directions of the DOAC.  Edoxaban and rivaroxaban have **ONCE daily administration** and apixaban and dabigatran are taken **TWICE daily**.  Edoxaban, apixaban and dabigatran can be taken **with or without food** and should be swallowed whole and do not chew (do not open dabigatran capsules).  Rivaroxaban should be taken with food.  Explain importance of good adherence to medication. |
| **Missed Dose** | Explain the the importance of good compliance. Explain that to ensure optimal protection from blood clots, never skip a dose and NOT to stop taking unless advised by a doctor.  If the patient misses a dose of edoxaban or rivaroxaban they should take it immediately and then continue the following day with the once-daily intake as recommended. The patient should **not** take double the prescribed dose on the same day to make up for a missed dose.  If a dose of apixaban is missed, the patient should take apixaban immediately and then continue with twice daily intake as before.  A missed dose of dabigatran may still be taken up to 6 hours prior to the next scheduled dose. From 6 hours prior to the next scheduled dose on, the missed dose should be omitted. |
| **General additional advice for DOACs** | It is important that patients inform other health professionals treating them, including their dentist and pharmacist that they are taking this medicine.  Inform a healthcare specialist if they need to have surgery or an invasive procedure.  Patients should seek urgent medical attention if they fall or injure themselves during treatment, especially if they hit their head, due to the increased risk of bleeding.  Lifestyle advice regarding contact sports or extreme sports should be included in the counseling where appropriate as an injury whilst taking a DOAC could cause serious bruising or bleeding. |
| **Reversal Agents** | There are reversal agents available which can be used in severe bleeding or if emergency surgery/procedure is required in an emergency under specific circumstances. See the SOP for further details. |
| **Alert Card** | Advise the patient/carer to always carry their alert card (supplied with medication) and always inform health professionals that they are taking an anticoagulant prior to any procedure. |
| **Weight change** | Advise that the patient should inform their GP about any significant weight change that results in their body weight going **above 60kg (9st 6.3lb) or below 61kg (9st 8.5lb)** as their dose may need to be changed. |
| **Monitored Dosage System?** | Check if patient uses a monitored dosage system and inform the community pharmacy if any change to treatment is required. |

**Appendix 6 – Decision Aid for Medicines Optimisation Review of Patients Prescribed Apixaban**

[Cheshire-and-Mersey-Decision-Aid-for-Medicines-Optimisation-Review-of-Patients-Prescribed-Apixaban-Sept-2022.pdf (england.nhs.uk)](https://www.england.nhs.uk/north-west/wp-content/uploads/sites/48/2022/09/Cheshire-and-Mersey-Decision-Aid-for-Medicines-Optimisation-Review-of-Patients-Prescribed-Apixaban-Sept-2022.pdf)

**Appendix 7 - Guide to Installing the DOAC Search with Reports**

The searches may require local adaptation, depending on how the reviews are being implemented and how the codes included in them are used in each area.

Copy and paste the embedded zip file to an appropriate location such as the desktop.



Unzip the folder by right clicking on the zip file and select “Extract all”. You will be asked to select a location to store the unzipped folder e.g., the desktop.

Click “Extract” and the unzipped folder will open showing 2 files: The C+M DOAC search with report (to identify patients for review) and a folder of searches to support capturing the total number of DOAC reviews and optimisations to Edoxaban completed.


**Installing the DOAC search with reports.**

Go to the EMIS globe and select Reporting>Population Reporting and select the folder where you want to import the search and reports, for example “Medicines Management”

On the population reporting toolbar select “import”. You will need to locate the Meds optimisation of DOACs folder (or create this if not previously done) and then select the XML document called “C+M DOAC search with report”. Click Open and then click OK.

The search and reports should be installed within a folder called “C+M DOAC search with report”.

Opening that folder should reveal the search and two reports as seen here.



To run the search and two reports simultaneously, right click on the “C+M DOAC search with report” folder and select “Run”. You can then view the results of the two reports.

Right click on the folder and select “run” to run the search and both reports together

A screenshot of a computer

Description automatically generated with medium confidence

**Appendix 8 – Installing the DOAC Review Template**

The DOAC Review template has been updated, so that the blood pressure included in the contra-indications is in line with NICE guidance of ‘stage 3’ or severe hypertension ≥180/120mmHg.

Unzip the folder by right clicking on the zip file and select “Extract all”. You will be asked to select a location to store the unzipped folder e.g., the desktop. Click “Extract” and the unzipped folder will open showing 1 file, the DOAC Review Template v2.

****

**Installing the template for the first time**

To import the Template into EMIS you will need to access resource publisher.

Go to the EMIS Globe > Configuration > Resource publisher.

The template requires a library item and concepts to be installed. It is recommended you first create a new folder for the library item and concepts so that you can easily find it in the future if needed.

Select Library items from the menu on the left of the screen. 

Click on the practice name. **Be careful NOT to select one of the subfolders**.

Graphical user interface, text, application

Description automatically generated

Practice name

Click Add > folder at the top left. Name the folder in an appropriate way for example “DOAC meds optimisation” and save it.

Now Select Concepts



Click on the practice name as before. Click Add > folder at the top left. Name the folder in an appropriate way for example “DOAC meds optimisation” and save it.

Now select Protocols and Templates from the left menu.



Select the folder where you want to install the template, for example “Medicines Management”.

Click “import” and find the xml document called “DOAC Review template” and select open. You will see a dialogue box as shown here.

It may take a few minutes for EMIS to prepare the concepts and library items. Graphical user interface, text, application, email

Description automatically generated

You will then see a dialogue box asking for you to select a destination folder for the concepts and library items.

Graphical user interface

Description automatically generated

Find and select the two folders you have just created and then select import.

You may find that the template is imported as a draft. Select Activate from the toolbar at the top of the screen.

Text

Description automatically generated with medium confidence

You may then be asked if you want to activate all linked draft resources. Select “activate all”.

You should now be able to run the template in a patient consultation. It is suggested you try this on a dummy patient first to ensure the template is working.

If you require any further support with the EMIS search or template, contact Helen Roberts – [Helen.Roberts@southseftonccg.nhs.uk](mailto:Helen.Roberts@southseftonccg.nhs.uk)

**Installing an updated version of the template**

1. Create a new folder in Concept Manager, name it Medicines optimisation of DOACs v2.
2. Archive previous folder.
3. Repeat the same in Library items.
4. Archive previous version of the template.
5. Import the v2 version of the template,

* select Medicines optimisation of DOACs v2 folder for importing concepts.
* Select Medicines optimisation of DOACs v2 folder for Library item.

1. Complete.
2. You may find that the template is imported as a draft. Select Activate from the toolbar at the top of the screen.
3. You may find you need to log out or refresh EMIS before the updated template appears.

**Appendix 9 – Final Outcomes Report**

|  |  |
| --- | --- |
| **PATIENTS WITH AF DOAC REVIEW SUMMARY** | |
| **CCG** |  |
| **GP PRACTICE** |  |
| **Number of patients reviewed** |  |
| **Number of patients without appropriate monitoring (minimum = once per 12 months)** |  |
| **Number of patients on INCORRECT dose of DOAC** |  |
| **No. of patients changed to alternative DOAC** |  |
| **No. of patients DOAC stopped** |  |
| **No. of patients changed to VKA or LMWH** |  |
| **No. of patients on incorrect dose due to Age** |  |
| **No. of patients on incorrect dose due to Weight** |  |
| **No. of patients on incorrect dose due to increase in CrCl** |  |
| **No. of patients on incorrect dose due to decrease in CrCl** |  |
| **No. of patients unable to complete due to no recent weight / bloods \*** |  |
| **Total number of interventions** |  |

**References**

1. NICE NG196. Atrial Fibrillation: Diagnosis and Management. April 2021 https://www.nice.org.uk/guidance/ng196
2. [NICE QS93](https://www.nice.org.uk/guidance/qs93). Atrial Fibrillation Quality Standard QS93. July 2015. <https://www.nice.org.uk/guidance/qs93>
3. Jan Steffel et al. The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. *European Heart Journal*, Volume 39, Issue 16, 21 April 2018, Pages 1330–1393
4. NHSE Operational note: National Procurement for DOACs version 1. Dec 2021
5. <https://www.medicines.org.uk/emc/> - edoxaban, apixaban, dabigatran and rivaroxaban
6. CHA2DS2-VASc Gregory Y H Lip, Robby Nieuwlaat, Ron Pisters, Deirdre A Lane, Harry J G M Crijns. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. Chest. 2010 Feb; 137 (2):263-72
7. Gerhard Hindricks, Tatjana Potpara, Nikolaos Dagres, Elena Arbelo, Jeroen J Bax, Carina Blomström-Lundqvist, Giuseppe Boriani, Manuel Castella, Gheorghe-Andrei Dan, Polychronis E Dilaveris, Laurent Fauchier, Gerasimos Filippatos, Jonathan M Kalman, Mark La Meir, Deirdre A Lane, Jean-Pierre Lebeau, Maddalena Lettino, Gregory Y H Lip, Fausto J Pinto, G Neil Thomas, Marco Valgimigli, Isabelle C Van Gelder, Bart P Van Putte, Caroline L Watkins, ESC Scientific Document Group, 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC, *European Heart Journal*, Volume 42, Issue 5, 1 February 2021, Pages 373–498, <https://doi.org/10.1093/eurheartj/ehaa612>
8. Ron Pisters, Deirdre A Lane, Robby Nieuwlaat, Cees B de Vos, Harry J G M Crijns, Gregory Y H Lip. A novel user-friendly (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest.2010;138(5):1093 - 1100
9. Emily C. O’Brien, DaJuanicia N. Simon, Laine E. Elaine M. Hylek, Bernard J. Gersh, Jack E. et al. The ORBIT bleeding score: a simple bedside score to assess bleeding risk in atrial fibrillation. European Heart Journal, Vol 36, Issue 46, 7 Dec 2015, Pages 3258 – 3264
10. NICE NG136. Hypertension in adults: Diagnosis and management. August 2019 https://www.nice.org.uk/guidance/ng136
11. NICE CG115. Alcohol-use disorders: diagnosis, assessment and management of harmful drinking (high-risk drinking) and alcohol dependence. February 2011 <https://www.nice.org.uk/guidance/cg115>